Sino Biopharmaceutical's Earnings Outlook Brighter on Higher Margins -- Market Talk

Dow Jones

08/19

0605 GMT - Sino Biopharmaceutical Will likely to see stronger earnings thanks to its higher gross margins, Nomura analysts write in a note. The company's 1H net profit rose 12% to CNY3.4 billion, beating Nomura's estimates, thanks to dividend income of CNY1.5 billion from the Sinovac investment, they say. The company's sales growth in 1H was driven by innovative drug sales of CNY7.8 billion, which accounted for 44% of its continued business revenue, they say. Nomura lifts its 2025 fiscal year's revenue estimates by 0.4%. Nomura raises the stock's target price to HK$9.17 from HK$7.69 and maintains a buy rating. Shares last at HK$7.32. (jiahui.huang@wsj.com; @ivy_jiahuihuang)

(END) Dow Jones Newswires

August 19, 2025 02:05 ET (06:05 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2560157702"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560157702\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560157702?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 14:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560157702","market":"sh","top_or_hot":-1,"title":"Sino Biopharmaceutical's Earnings Outlook Brighter on Higher Margins -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0605 GMT - <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> Will likely to see stronger earnings thanks to its higher gross margins, Nomura analysts write in a note. The company's 1H net profit rose 12% to CNY3.4 billion, beating Nomura's estimates, thanks to dividend income of CNY1.5 billion from the Sinovac investment, they say. The company's sales growth in 1H was driven by innovative drug sales of CNY7.8 billion, which accounted for 44% of its continued business revenue, they say. Nomura lifts its 2025 fiscal year's revenue estimates by 0.4%. Nomura raises the stock's target price to HK$9.17 from HK$7.69 and maintains a buy rating. Shares last at HK$7.32. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 19, 2025 02:05 ET (06:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sino Biopharmaceutical's Earnings Outlook Brighter on Higher Margins -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSino Biopharmaceutical's Earnings Outlook Brighter on Higher Margins -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-19 14:05</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0605 GMT - <a href=\"https://laohu8.com/S/SBHMY\">Sino Biopharmaceutical</a> Will likely to see stronger earnings thanks to its higher gross margins, Nomura analysts write in a note. The company's 1H net profit rose 12% to CNY3.4 billion, beating Nomura's estimates, thanks to dividend income of CNY1.5 billion from the Sinovac investment, they say. The company's sales growth in 1H was driven by innovative drug sales of CNY7.8 billion, which accounted for 44% of its continued business revenue, they say. Nomura lifts its 2025 fiscal year's revenue estimates by 0.4%. Nomura raises the stock's target price to HK$9.17 from HK$7.69 and maintains a buy rating. Shares last at HK$7.32. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 19, 2025 02:05 ET (06:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2560157702","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560157702","pubTimestamp":1755583500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0605 GMT - Sino Biopharmaceutical Will likely to see stronger earnings thanks to its higher gross margins, Nomura analysts write in a note. The company's 1H net profit rose 12% to CNY3.4 billion, beating Nomura's estimates, thanks to dividend income of CNY1.5 billion from the Sinovac investment, they say. The company's sales growth in 1H was driven by innovative drug sales of CNY7.8 billion, which accounted for 44% of its continued business revenue, they say. Nomura lifts its 2025 fiscal year's revenue estimates by 0.4%. Nomura raises the stock's target price to HK$9.17 from HK$7.69 and maintains a buy rating. Shares last at HK$7.32. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"01177":"中国生物制药"},"translate_title":"中国生物制药盈利前景因利润率上升而更加光明——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":0.9},"content_text":"0605 GMT - Sino Biopharmaceutical Will likely to see stronger earnings thanks to its higher gross margins, Nomura analysts write in a note. The company's 1H net profit rose 12% to CNY3.4 billion, beating Nomura's estimates, thanks to dividend income of CNY1.5 billion from the Sinovac investment, they say. The company's sales growth in 1H was driven by innovative drug sales of CNY7.8 billion, which accounted for 44% of its continued business revenue, they say. Nomura lifts its 2025 fiscal year's revenue estimates by 0.4%. Nomura raises the stock's target price to HK$9.17 from HK$7.69 and maintains a buy rating. Shares last at HK$7.32. (jiahui.huang@wsj.com; @ivy_jiahuihuang) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 19, 2025 02:05 ET (06:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}